Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06428890
Other study ID # 030-2223-EXP
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 1, 2022
Est. completion date April 1, 2024

Study information

Verified date May 2024
Source California Baptist University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aimed to assess the effect of the supplementation with grape seed extract (GSE) on blood pressure during static handgrip exercise and muscle metaboreflex in individuals with elevated and state 1 hypertension.


Description:

Muscle metatoreflex (MMR) has been known to play an important role in adjusting hemodynamic responses during exercise. The reflex increases sympathetic activity to heart and blood vessels to increase blood supply to contracting skeletal muscles. On the other hand, studies demonstrated that abnormal cardiovascular responses occurred by the overactive MMR in pathological conditions such as hypertension, diabetes, and congestive heart failure. Excessive blood pressure (BP) responses to exercise induce cardiovascular events such as stroke, heart attack, and coronary artery disease. Previously, a study found that dietary supplementation with grape seed extract (GSE) reduced BP response to dynamic exercise in individuals with elevated and stage 1 hypertension (ES1H) and associated with peripheral vasodilation. However, mechanisms underlying this phenomenon are not clear. Purpose: therefore, the purpose of this study is to investigate whether chronic dietary supplementation with GSE can decrease BP responses to exercise and this observation is associated with reduced MMR. Methods: 12 ES1H males were studied. Changes in cardiac output (Q), mean arterial pressure (MAP) and total peripheral resistance (TPR) were compared between the GSE and placebo supplementations during static handgrip exercise (SHE) and post exercise muscular ischemia (PEMI). Participants completed 3 min of SHE at 40% of MVC followed by 2 min of PEMI.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date April 1, 2024
Est. primary completion date April 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 30 Years
Eligibility Inclusion Criteria: - systolic blood pressure: 120-139 mmHg and/or a diastolic blood pressure: 80-89 mmHg Exclusion Criteria: - taking medications that could affect cardiovascular function or BP

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Grape Seed Extract
dietary supplements that rich in polyphenolic compounds
Placebo
Starch

Locations

Country Name City State
United States California Baptist University Riverside California

Sponsors (1)

Lead Sponsor Collaborator
California Baptist University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary heart rate (bpm) measured these variables at rest and during static handgrip exercise and muscle metaboreflex 5 minutes, 3 minutes, and 2 minutes, respectively.
Primary stroke volume (ml) measured these variables at rest and during static handgrip exercise and muscle metaboreflex 5 minutes, 3 minutes, and 2 minutes, respectively.
Primary cardiac output (l/min) measured these variables at rest and during static handgrip exercise and muscle metaboreflex 5 minutes, 3 minutes, and 2 minutes, respectively.
Primary systolic blood pressure (mmHg) measured these variables at rest and during static handgrip exercise and muscle metaboreflex 5 minutes, 3 minutes, and 2 minutes, respectively.
Primary diastolic blood pressure (mmHg) measured these variables at rest and during static handgrip exercise and muscle metaboreflex 5 minutes, 3 minutes, and 2 minutes, respectively.
Primary total peripheral resistance (mmHg/l/min) measured these variables at rest and during static handgrip exercise and muscle metaboreflex 5 minutes, 3 minutes, and 2 minutes, respectively.
See also
  Status Clinical Trial Phase
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Completed NCT02551640 - Improving Physical Activity Through a mHealth Intervention in Cardio-metabolic Risk Patients N/A
Recruiting NCT01483430 - Effect of Ginseol Kg1 on Blood Pressure Lowering Phase 3
Completed NCT01637909 - Korean Life-Style Modification Effects on Blood Pressure N/A
Terminated NCT01295216 - Use of Mobile Technology to Prevent Progression of Pre-hypertension in Latin American Urban Settings N/A
Unknown status NCT01308983 - Study of Amiloride on Vascular Phenotypes in Young Adults With Prehypertension Phase 4
Active, not recruiting NCT03596099 - Rice Vinegar as an Intervention to Lower Blood Pressure in Adults With Prehypertension and 10-year CVD Risk <10% N/A
Completed NCT04326686 - Measuring Individual Responses to a Wholegrains and Nuts Intervention to Reduce Blood Pressure in Prehypertension N/A
Completed NCT03898518 - The Effects of a Jump Rope Exercise Program on Body Composition and Self-efficacy in Obese Adolescent Girls N/A
Terminated NCT01983462 - Vascular Dysfunction in Human Obesity Hypertension Phase 2
Completed NCT01458496 - Health Coaching to Effect Lifestyle Behaviour Change N/A
Completed NCT01472692 - Study of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood Pressure Phase 4
Completed NCT03266510 - Inspiratory Muscle Strength Training to Improve Blood Pressure and Physiological Function N/A
Completed NCT02998840 - A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure Phase 2
Completed NCT01974570 - Effect and Safety of Marealis RPC (Refined Peptide Concentrate) in Mild or Moderate Hypertensive Subjects Phase 2
Completed NCT02326766 - Blood Pressure Lowering Effect of Supplementation With Korea Red Ginseng Associated With Reductions in Circulating Lp-PLA2 Activity and Lysophospatidylcholines and an Increase in Dihydrobiopterin in Prehypertensive Subjects Phase 3
Completed NCT01395329 - Nebivolol and the Endothelin (ET)-1 System Phase 4
Completed NCT01331486 - Nitric Oxide Mediated Vasodilatory Response to Hawthorn Standardized Extract Phase 1
Completed NCT05274971 - Diet and Exercise on Ambulatory Blood Pressure N/A
Active, not recruiting NCT02371317 - Stress Management for High Blood Pressure N/A